Structure Therapeutics Inc - American Depositary Shares — Bilancio Trimestrale (NASDAQ:GPCR) | MetaTrader

Apri il grafico completo

Notizie

Structure Therapeutics nomina Matthew Lang COO e consulente legale

Does NVO Face Rising Competitive Pressure on LLY's Foundayo Approval?

Structure Therapeutics: The Oral Obesity Inflection, Best-In-Class Efficacy

Structure Therapeutics: A High-Risk, High-Reward Bet On The Next GLP-1 Blockbuster (GPCR)

Wolfe Research avvia la copertura su Structure Therapeutics con rating Peerperform

NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?

Eli Lilly's Experimental Drug Retatrutide Delivers Strong Weight Loss In Late-Stage Trial

Why Did Eli Lilly Stock Slide 6% Despite Strong GLP-1 Momentum?

BMO raises Structure Therapeutics stock price target on obesity drug data

Structure Therapeutics' GLP-1 Agonist Could Be A Potential Acquisition Target (GPCR)

H.C. Wainwright riduce il target su Structure Therapeutics

H.C. Wainwright lowers Structure Therapeutics price target on penetration assumptions